CD33 and B-cell acute lymphoblastic leukemia: It constitutes an alternative, promising anti-CD33 immunotherapeutic approach that further builds on the clinical approval of anti-CD19 CAR T cells (Kymriah) to treat B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma [43].